2,330
Views
2
CrossRef citations to date
0
Altmetric
Case Report

End-Stage Renal Disease Following Carboplatin Chemotherapy for a Nasopharyngeal Carcinoma

, &
Pages 1049-1051 | Published online: 07 Jul 2009

REFERENCES

  • Wolfgang GH, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol. 1994; 22: 73–79
  • Martinez F, Deray G, Dubois M, et al. Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs. 1993; 4: 85–90
  • Stohr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007; 48: 140–147
  • Agraharkar M, Nerenstone S, Palmisano J, Kaplan AA. Carboplatin-related hematuria and acute renal failure. Am J Kidney Dis. 1998; 32: E5
  • Inbar M, Merimsky O, Chaitchik S. Carboplatin-related idiosyncrasy. Anticancer Drugs. 1995; 6: 775–776
  • McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: A report of two cases and review of the literature. Am J Med. 1991; 90: 386–391
  • Teo PML, Leung SF, Yu P, Tsao SY, Foo W, Shiu W. A comparison of Ho's, International Union against Cancer, and American Joint Committee Stage Classifications for nasopharyngeal carcinoma. Cancer. 1991; 67: 434–439
  • Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17: 409–422
  • Frenkel J, Kool G, de Kraker J. Acute renal failure in high dose carboplatin chemotherapy. Med Pediatr Oncol. 1995; 25: 473–474
  • Deray G, Ben-Othman T, Brillet G, et al. Carboplatin-induced acute renal failure. Am J Nephrol. 1990; 10: 431–432
  • Wright JE, Elias A, Tretyakov O, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995; 36: 345–351
  • Squibb Bristol-Myers. Paraplatin-AQ product monograph. Princeton, NJ January, 2004
  • Butani L, West DC, Taylor DS. End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation. Pediatr Transplant. 2003; 7: 408–412
  • Karim M, Vaux E, Davies DR, Mason PD. Renal failure due to scleroderma with thrombotic microangiopathy developing in a woman treated with carboplatin for ovarian cancer. Clin Nephrol. 2002; 58: 384–388
  • Thomas H, Boddy AV, English MW, et al. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial. J Clin Oncol. 2000; 18: 3614–3621

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.